As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide
TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic
It’s a two-dose vaccine administered 28 days apart
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
